Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a
Open Orphan plc distribution in specie of Poolbeg Pharma plc shares – Q&A
Open Orphan distribution in specie shares and in particular some people had been concerned that they were unable to trade them.
Open Orphan PLC (AIM: ORPH) Appointment of Chief Executive Officer
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan PLC (ORPH.L) Imutex Vaccine Phase I Study Results
mutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results
Open Orphan PLC (ORPH.L) £5.1m RSV Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) £1.5m Contract renewal for Venn Life Sciences
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan PLC (ORPH.L) Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment